Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial

BACKGROUND: More clinical practice need to be performed to verify the toxicity of the hypofractionated radiotherapy (HFRT) combined with PD-1 blockade in lung cancer. This phase I study aimed to investigate the safety and efficacy of nivolumab combined with HFRT in patients with progressive advanced...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Ye, Hua, Pang, Haowen, Shi, Xiangxiang, Ren, Peirong, Huang, Shangke, Yu, Hong, Wu, Jingbo, Lin, Sheng
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100893/
https://ncbi.nlm.nih.gov/pubmed/33968760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.657024
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky